BC
EW icon

Bayforest Capital’s Edwards Lifesciences EW Stock Holding History

Bayforest Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,842
Closed -$148K – 1034
2026
Q1 		$148K Sell
1,842
-1,148
-38% -$94.6K 0.17% 221
2025
Q4 		$255K Buy
2,990
+820
+38% +$67.3K 0.19% 201
2025
Q3 		$169K Buy
+2,170
New +$170K 0.08% 423
2025
Q1 		– Sell
-1,084
Closed -$80.2K – 780
2024
Q4 		$80.2K Buy
+1,084
New +$75.9K 0.1% 362

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Bayforest Capital's EW Position: Q2 2026 in Review

Bayforest Capital sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 1,842 shares — an estimated $148K sold.

Bayforest Capital first reported a position in EW in Q4 2024 and held it in 4 quarters. The position peaked at $255K in Q4 2025. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Bayforest Capital reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Bayforest Capital sold 1,842 Edwards Lifesciences shares in Q2 2026, an estimated $148K.
  • Bayforest Capital first reported a position in Edwards Lifesciences in Q4 2024 and held it in 4 quarters.
  • Bayforest Capital's Edwards Lifesciences position peaked at $255K in Q4 2025.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.